Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. (2016)

First Author: Baumert BG
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(16)30313-8

PubMed Identifier: 27686946

Publication URI: http://europepmc.org/abstract/MED/27686946

Type: Journal Article/Review

Volume: 17

Parent Publication: The Lancet. Oncology

Issue: 11

ISSN: 1470-2045